NCT05977088 Prediction of Effectiveness of rTMS Application in Alzheimer's Patients
| NCT ID | NCT05977088 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istanbul Medipol University Hospital |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2022-02-16 |
| Primary Completion | 2025-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2022-02-16 with a primary completion date of 2025-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Since pharmacological methods are insufficient in the treatment processes of Alzheimer's disease, non-pharmacological methods such as Transcranial Magnetic Stimulation (TMS) have started to be tried as a treatment option as in other neurological and psychiatric diseases. Repeated (rTMS) offers a potential treatment pathway for neurological and psychiatric illnesses. rTMS benefit rate may vary depending on many factors such as the region where it is applied, the progression and the disease degree. The possible effects of TMS on Alzheimer's pathophysiology and modification of disease process (neuroprotective, anti-inflammatory and antioxidant) will also be revealed through blood samples taken from patients before and after treatment. These approaches also constitute the original value of our study.
Eligibility Criteria
Inclusion Criteria: * Have been diagnosed with clinical Alzheimer's Disease in accordance with the NINCDS-ADRDA diagnostic criteria * \>55 years old * Clinical Dementia Rating Scale (CDR) score in the 1-2 range * Not having any other disease that affects their cognitive functions * Volunteer to participate in the study Exclusion Criteria: * Participant or relative does not give consent * The patient's inability to participate in the entire study procedure (eg living in another city) * The patient's history of head trauma with alcohol/substance abuse * Presence of severe stroke and other neurological sequelae disease in the participant * Presence of a metal implant on the head or having a pacemaker and contraindications for other TMS applications During the study or 1 month before, having/been receiving/receiving an investigational drug targeting Alzheimer's disease or neuromodulation treatment such as tDCS and TMS, other than standard treatment for AD symptom control such as acetylcholine esterase and memantine, with the potential to affect the study
Contact & Investigator
Lutfu Hanoglu, Prof. DR. MD
PRINCIPAL INVESTIGATOR
Medipol University
Frequently Asked Questions
Who can join the NCT05977088 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05977088 currently recruiting?
Yes, NCT05977088 is actively recruiting participants. Contact the research team at lhanoglu@kure.com.tr for enrollment information.
Where is the NCT05977088 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT05977088 clinical trial?
NCT05977088 is sponsored by Istanbul Medipol University Hospital. The principal investigator is Lutfu Hanoglu, Prof. DR. MD at Medipol University. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.